title: Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids.
abstract: Dorsal skin reactions to continuous topical treatment with different types of corticosteroids were histologically investigated in hairless descendants of Mexican hairless dogs. The preparations tested were prednisolone (ST-1; weak), fluocinolone acetonide (ST-2; moderate), diflucortolone valrerate (ST-3; strong), and mometasone furoate (ST-4; very strong). Grossly, the sites treated with ST-3 and ST-4 showed moderate inflammatory reactions. After completion of the corticosteroid treatment, both sites were less pigmented and had a thin texture. The severity of histologic changes in the skin was dependent on the efficacy of the corticosteroids. The epidermis was prominently thinned from 1 wk after treatment with the corticosteroids, resulting in a flat dermis-epidermis junction. By the end of the corticosteroid treatment, these lesions became progressively more severe. At 2 wk after completion of topical treatment, the epidermal thickness in the sites treated with ST-1 and ST-2 began to return to normal values, whereas the epidermis of the skin treated with ST-3 and ST-4 became thinner. At 3-4 wk after topical treatment with ST-3 and ST-4, the dermis showed hyalinization of collagen bundles. These dermatologic findings in hairless dogs are in accordance with steroid-induced skin atrophy of human beings. These results suggest that the skin of hairless dogs responds sensitively to topical corticosteroids and that these animals are a useful model for investigating the efficacy and adverse effects of cutaneous topical corticosteroids.
authors.affiliation: Research Center, Nihon Nosan Kogyo Co., Takura, Tsukuba, Ibaraki, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kimura
authors.forename: K
authors.initials: K
authors.lastname: Doi
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology*; D001284:Atrophy / Q000139:chemically induced; D020405:Dermis / Q000187:drug effects / Q000473:pathology; D004060:Diflucortolone / Q000009:adverse effects / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D004817:Epidermis / Q000187:drug effects / Q000473:pathology; D005260:Female; D005446:Fluocinolone Acetonide / Q000009:adverse effects / Q000494:pharmacology; D005938:Glucocorticoids; D018859:Hair Follicle / Q000187:drug effects; D007642:Keratosis / Q000139:chemically induced / Q000473:pathology; D008297:Male; D000068656:Mometasone Furoate; D011239:Prednisolone / Q000009:adverse effects / Q000494:pharmacology; D011244:Pregnadienediols / Q000009:adverse effects / Q000494:pharmacology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D005446:Fluocinolone Acetonide; D011239:Prednisolone; D004060:Diflucortolone